Evidence map›Paper›PMID 40253609›Full record

ArticleACS nano2025

Differential Sensitivity to Interepitope Spacing in Mast Cells and B Cells Enables Design of Hypoallergenic Allergen Vaccine Immunogens.

Benjamin J Cossette, Luyao Shen, Andrés Bermudez, Helena Freire Haddad, Shamitha Shetty, Justin Sylvers, Fan Yuan, Yonggang Ke, Joel H Collier

Abstract read
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benjamin J CossetteDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.
Luyao ShenWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University Atlanta, Atlanta, Georgia 30322, United States.ORCID 0000-0002-3231-4878
Andrés BermudezDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0009-0002-7201-8245
Helena Freire HaddadDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.
Shamitha ShettyDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.
Justin SylversDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.
Fan YuanDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.
Yonggang KeWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University Atlanta, Atlanta, Georgia 30322, United States.ORCID 0000-0003-1673-2153

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
Equipment Supplement: Cell sorting flow cytometry to support the BTDDRM1GM145394 · NIGMS · EMORY UNIVERSITY · PI Khalid S. Salaita · 2023 to 2026
$5.6M
The lambda bacteriophage regulatory loopR01GM084070 · NIGMS · EMORY UNIVERSITY · PI FINZI, LAURA · 2009 to 2021
$4.1M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
DNA nanodevices for molecular interrogation and regulation of lymphocytes in adaptive immune systemR35GM153472 · NIGMS · EMORY UNIVERSITY · PI Yonggang Ke · 2024 to 2026
$1.4M
Supramolecular peptide immunotherapies for peanut allergyR21AI164740 · NIAID · DUKE UNIVERSITY · PI COLLIER, JOEL H · 2021 to 2022
$435k
NCI NIH HHS P30 CA014236NIAID NIH HHS R21 AI164740NIGMS NIH HHS R01 GM084070NIGMS NIH HHS R35 GM153472NIGMS NIH HHS RM1 GM145394NIGMS NIH HHS T32 GM008555NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

Therapeutic allergen vaccine immunogens can trigger IgE-mediated mast cell activation, resulting in allergic reactions. Here, we report on a mode of hypoallergenic immunogen design that enables immunization against IgE-reactive peptide B cell epitopes by optimizing the distance between epitopes. Using DNA-based model immunogens, we show that mast cells and B cells exhibit idiosyncratic sensitivity to interepitope spacing, with mast cell activation being dampened by high interepitope spacing while B cells remain responsive to identical immunogen configurations. To exploit this finding, we construct hypoallergenic immunogens based on supramolecular peptide nanofibers with ultralow epitope density that, when used as an allergen vaccine, raise protective allergen-neutralizing IgG antibody responses. This study provides a proof-of-concept for a mode of hypoallergenic immunogen design based on nanoscale control of the distances between IgE-reactive epitopes, which may enable allergen vaccination against IgE-reactive epitope targets in the absence of allergic reactogenicity.

Indexed as

AllergensB-LymphocytesEpitopesEpitopes, B-LymphocyteMast CellsVaccinesAnimalsHumansImmunoglobulin EMicePeptidesAllergensEpitopesEpitopes, B-LymphocyteImmunoglobulin EPeptidesVaccinesallergenhypoallergenicimmunotherapynanofiberpeptidevaccine

Identifiers

PMID40253609
PMCPMC12175069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.